Research programme: iron chelators - Metabolic Pharmaceuticals
Alternative Names: MBP 0201Latest Information Update: 16 Jul 2016
At a glance
- Originator Metabolic Pharmaceuticals
- Class
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Iron overload
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Iron-overload in Australia
- 02 Jul 2004 Preclinical trials in Iron overload in Australia (unspecified route)